Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Stem cells in chronic myelogenous leukemia

C M Verfaillie1

  • 1Department of Medicine, University of Minnesota, Minneapolis, USA.

Hematology/Oncology Clinics of North America
|January 27, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Altered neuronal network and rescue in a human MECP2 duplication model.

Molecular psychiatry·2015
Same author

Scalable expansion of multipotent adult progenitor cells as three-dimensional cell aggregates.

Biotechnology and bioengineering·2010
Same author

Expansion and hepatic differentiation of rat multipotent adult progenitor cells in microcarrier suspension culture.

Journal of biotechnology·2010
Same author

Assays to determine hematopoietic stem cell content in blood or marrow grafts.

Cytotherapy·2009
Same author

Stem and progenitor cells for liver repopulation: can we standardise the process from bench to bedside?

Gut·2008
Same author

Stem cell research: future implications for internal medicine.

Acta clinica Belgica·2006

Chronic myelogenous leukemia (CML) is a stem cell disease driven by the BCR-ABL oncogene. Malignant stem cells in CML respond abnormally to growth signals due to genetic defects.

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • The BCR-ABL fusion gene is a key driver in chronic myelogenous leukemia (CML).
  • Understanding the molecular basis of CML is crucial for developing targeted therapies.

Purpose of the Study:

  • To review the molecular consequences of the BCR-ABL oncogene.
  • To examine the evidence for CML as a clonal hematopoietic stem cell disease.

Main Methods:

  • Literature review of current evidence.
  • Discussion of molecular mechanisms.

Main Results:

  • CML originates from a malignant hematopoietic stem cell.
  • BCR-ABL oncogene-induced defects alter stem and progenitor cell responses.

Related Experiment Videos

  • Malignant cells respond to normal stimuli but with altered outcomes.

    • Conclusions:

    • CML is a clonal stem cell disorder characterized by BCR-ABL oncogene-driven abnormalities.
    • These abnormalities lead to dysregulated proliferation and differentiation of hematopoietic stem and progenitor cells.